|
ALBA Therapeutics Corporation |
|
|
Suite 400, 800 West Baltimore Street
Baltimore, MD 21201 USA
phone:410-319-0780
fax:410-244-8616
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.albatherapeutics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pharmaceuticals for the treatment of inflammatory and immune mediated diseases. |
|
| Management |
| Bruce A. Peacock, Chief Executive Officer; Sefik Alkan, PhD, Executive Vice President, Discovery; Jeffrey W. Church, CPA,
Chief Financial Officer; Anne Shiflett, CPA, Vice President,
Finance & Administration; Sharon Rowland, PhD, RAC, Vice President, Regulatory Affairs & Quality; Francisco Leon, MD, PhD, Vice President, Clinical Development & Medical Affairs;
Wendy Perrow, MBA, Vice President, Marketing & Alliance Management; Linda Arterburn, PhD, Vice President, Preclinical Development & Program Management; Roberto N. Allen, Esq., Vice President, Legal Affairs & Intellectual Property; Mark Ginski, PhD, Senior Director, Product & Analytical Development |
| |
|
|
| |
|
| Keywords |
| inflammatory, immune, zonulin, antagonist, gastrointestinal, metabolic, pulmonary, renal |
|
|
|
| Description |
|
Alba Therapeutics Corporation is focused on the development, production and marketing of pharmaceuticals for the treatment of inflammatory and immune mediated diseases. |
|
| Products / Services |
Current therapeutic areas of focus for Alba's zonulin antagonists include immune-based disorders, a diverse classification that encompasses gastrointestinal, metabolic, pulmonary, and renal disease states, among others. The ability of Alba's lead zonulin agonist to increase transport across epithelial and endothelial boundaries has resulted in animal proof-of-concept studies that demonstrate increased drug bioavailability and potent mucosal vaccine efficacy.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members